These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31748278)

  • 1. Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer.
    Wang F; Reid S; Zheng W; Pal T; Meszoely I; Mayer IA; Bailey CE; Park BH; Shu XO
    Clin Cancer Res; 2020 Jan; 26(1):101-109. PubMed ID: 31748278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
    Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
    Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Characterization and Mortality From Breast Cancer in Men.
    Massarweh SA; Sledge GW; Miller DP; McCullough D; Petkov VI; Shak S
    J Clin Oncol; 2018 May; 36(14):1396-1404. PubMed ID: 29584547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
    Altman AM; Kizy S; Yuan J; Denbo JW; Jensen EH; Hui JYC; Tuttle TM; Marmor S
    Ann Surg Oncol; 2018 Aug; 25(8):2296-2302. PubMed ID: 29907942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
    Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
    Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
    Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
    Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX® test data: a retrospective multicenter study in Japan.
    Tsuchida Y; Niikura N; Chishima T; Mizuno M; Kawate T; Fuchikami H; Miyoshi Y; Sakai T; Kotani H; Kondo N; Hayashi N
    Breast Cancer; 2024 May; 31(3):401-408. PubMed ID: 38451415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for Survival and Distribution of 21-Gene Recurrence Score in Patients With Pure Mucinous Breast Cancer: A SEER Population-Based Retrospective Analysis.
    Ding S; Wu J; Lin C; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2019 Feb; 19(1):e66-e73. PubMed ID: 30396812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
    Reyes SA; De La Cruz LM; Ru M; Pisapati KV; Port E
    Ann Surg Oncol; 2019 Oct; 26(10):3397-3408. PubMed ID: 31429016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
    Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
    J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
    Ibraheem AF; Press DJ; Olopade OI; Huo D
    Cancer; 2019 Jan; 125(2):213-222. PubMed ID: 30387876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J; Kim M; Fineberg S
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.
    Yoo SH; Kim TY; Kim M; Lee KH; Lee E; Lee HB; Moon HG; Han W; Noh DY; Han SW; Kim TY; Im SA
    Clin Breast Cancer; 2020 Apr; 20(2):98-107.e1. PubMed ID: 31522959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
    Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
    BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.